LT3037089T - Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti - Google Patents

Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti

Info

Publication number: LT3037089T
Authority: LT; Lithuania
Prior art keywords: eikozapentaenic; hypertriglycidemia; ethyl ester; acid ethyl; acid
Prior art date: 2009-02-10

Application number

LTEP16152447.5T

Other languages

English (en)

Inventor

Mehar Manku

Ian Osterloh

Pierre Wicker

Rene Braeckman

Paresh Soni

Original Assignee

Amarin Pharmaceuticals Ireland Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-10

Filing date

2010-02-09

Publication date

2020-01-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3037089(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-09 Application filed by Amarin Pharmaceuticals Ireland Limited filed Critical Amarin Pharmaceuticals Ireland Limited

2020-01-10 Publication of LT3037089T publication Critical patent/LT3037089T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LTEP16152447.5T 2009-02-10 2010-02-09 Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti LT3037089T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15129109P	2009-02-10	2009-02-10
US17375509P	2009-04-29	2009-04-29

Publications (1)

Publication Number	Publication Date
LT3037089T true LT3037089T (lt)	2020-01-10

Family

ID=42102041

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP13156122.7T LT2596786T (lt)	2009-02-10	2010-02-09	Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti
LTEP16152447.5T LT3037089T (lt)	2009-02-10	2010-02-09	Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP13156122.7T LT2596786T (lt)	2009-02-10	2010-02-09	Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti

Country Status (23)

Country	Link
US (29)	US8293727B2 (lt)
EP (5)	EP3037089B1 (lt)
KR (2)	KR101383006B1 (lt)
AU (1)	AU2010213899B2 (lt)
BR (1)	BRPI1007518A2 (lt)
CA (3)	CA3089847C (lt)
CY (2)	CY1122628T1 (lt)
DK (3)	DK2596786T3 (lt)
ES (3)	ES2768091T3 (lt)
HR (3)	HRP20130811T1 (lt)
HU (1)	HUE048299T2 (lt)
LT (2)	LT2596786T (lt)
MX (1)	MX2011008448A (lt)
NZ (1)	NZ594395A (lt)
PH (1)	PH12015500407B1 (lt)
PL (3)	PL2395991T3 (lt)
PT (3)	PT2596786T (lt)
RU (2)	RU2505292C2 (lt)
SG (3)	SG173612A1 (lt)
SI (3)	SI2596786T1 (lt)
SM (3)	SMT202000078T1 (lt)
WO (1)	WO2010093634A1 (lt)
ZA (1)	ZA201105612B (lt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
EP4137128A1 (en)	2008-09-02	2023-02-22	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
US9314444B2 (en)	2009-01-12	2016-04-19	Biokier, Inc.	Composition and method for treatment of NASH
US9006288B2 (en)	2009-01-12	2015-04-14	Biokier, Inc.	Composition and method for treatment of diabetes
US8470885B2 (en)	2009-01-12	2013-06-25	Biokier, Inc.	Composition and method for treatment of diabetes
ES2768091T3 (es)	2009-02-10	2020-06-19	Amarin Pharmaceuticals Ie Ltd	Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
MX350088B (es)	2009-04-29	2017-08-25	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
NZ720946A (en)	2009-04-29	2017-09-29	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh)	2009-06-15	2018-06-01	阿马里纳制药公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en)	2009-09-23	2011-03-24	Amarin Pharma, Inc.	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2480246A4 (en)	2009-09-23	2013-02-27	Biokier Inc	COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES
US20110178105A1 (en)	2010-01-15	2011-07-21	E.I. Du Pont De Nemours And Company	Clinical benefits of eicosapentaenoic acid in humans
PH12012501755A1 (en) *	2010-03-04	2012-11-12	Amarin Pharma Inc	Compositions and methods for treating and/or preventing cardiovascular disease
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en)	2010-11-29	2017-03-31	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8715648B2 (en)	2011-02-16	2014-05-06	Pivotal Therapeutics Inc.	Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en)	2011-02-16	2015-09-01	Pivotal Therapeutics, Inc.	Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US20130131170A1 (en) *	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
CN107050457A (zh)	2012-01-06	2017-08-18	翁特拉制药公司	游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
ES2891473T3 (es) *	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
EP2846790A4 (en) *	2012-02-14	2016-03-23	Photonz Corp Ltd	METHOD OF SUPERVISING THE CONSUMPTION OF AN ALICAMENT COMPRISING EICOSAPENTAENOIC ACID FOR THE PREVENTION AND / OR MANAGEMENT OF A DISEASE OR A CONDITION OF THE DISEASE
EP2846779A4 (en)	2012-05-07	2015-12-16	Omthera Pharmaceuticals Inc	STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
KR20200074259A (ko) *	2012-05-15	2020-06-24	모치다 세이야쿠 가부시키가이샤	고혈중 고감도 c반응성 단백질 환자의 심혈관 질병 1차 예방제
US20130324607A1 (en) *	2012-06-05	2013-12-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypercholesterolemia
WO2013192109A1 (en)	2012-06-17	2013-12-27	Matinas Biopharma, Inc.	Omega-3 pentaenoic acid compositions and methods of use
US20150157593A1 (en) *	2012-06-29	2015-06-11	Amarin Pharmaceuticals Ireland Limited	Methods of reducing ldl-p
CA3067012C (en) *	2012-06-29	2021-10-05	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20140004183A1 (en) *	2012-06-29	2014-01-02	Amarin Pharmaceuticals Ireland Limited	Methods for treating cardiovascular disease in statin-tolerant subjects
US20140005265A1 (en) *	2012-06-29	2014-01-02	Amarin Pharmaceuticals Ireland Limited	Methods for treating hypertriglyceridemia
WO2014050692A1 (ja) *	2012-09-28	2014-04-03	持田製薬株式会社	糖尿病新規発症低減用組成物
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US10123986B2 (en)	2012-12-24	2018-11-13	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en)	2012-12-24	2017-04-25	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US20140213648A1 (en) *	2012-12-31	2014-07-31	Amarin Pharmaceuticals Ireland Limited	Methods of increasing epa blood levels
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140221452A1 (en) *	2013-02-06	2014-08-07	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US20140221358A1 (en) *	2013-02-06	2014-08-07	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
JP2016518315A (ja) *	2013-03-13	2016-06-23	マティナスバイオファーマインコーポレイテッド	ω３ペンタエン酸組成物および使用方法
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
KR102039522B1 (ko) *	2013-06-03	2019-11-26	휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피.	근거리 무선 통신(ｎｆｃ)을 이용한 ｎｆｃ 태그의 기록방법 및 장치
US20140357717A1 (en) *	2013-06-04	2014-12-04	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6804823B2 (ja) *	2013-10-14	2020-12-23	アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーＡｒｉｚｏｎａＢｏａｒｄｏｆＲｅｇｅｎｔｓｏｎｂｅｈａｌｆｏｆＡｒｉｚｏｎａＳｔａｔｅＵｎｉｖｅｒｓｉｔｙ	白金錯体およびデバイス
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016175575A1 (ko) *	2015-04-30	2016-11-03	엘지전자(주)	블루투스 메쉬 네트워크를 이용하여 데이터를 송수신하기 위한 방법 및 장치
US10183044B2 (en)	2015-05-15	2019-01-22	P Tech, Llc	Systems and methods for thrombosis prevention
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
JP2021501210A (ja)	2017-10-30	2021-01-14	モントリオールハートインスティテュート	血漿コレステロールの上昇を処置する方法
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr)	2018-09-24	2020-12-16	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
JP7829478B2 (ja) *	2019-08-05	2026-03-13	アローヘッドファーマシューティカルズインコーポレイテッド	Ａｐｏｃ３関連疾患および障害の処置のための方法
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4377526A (en)	1981-05-15	1983-03-22	Nippon Suisan Kaisha, Ltd.	Method of purifying eicosapentaenoic acid and its esters
CA1239587A (en)	1983-10-24	1988-07-26	David Rubin	Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en)	1983-10-24	1985-07-02	Century Laboratories, Inc.	Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS6135356A (ja) *	1984-07-27	1986-02-19	Nippon Oil & Fats Co Ltd	血液脂質脂肪酸の分析方法
US4920098A (en)	1986-09-17	1990-04-24	Baxter International Inc.	Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en)	1987-04-27	1993-10-12	Scotia Holdings Plc	Lithium salt-containing pharmaceutical compositions
US5198468A (en)	1987-06-24	1993-03-30	Efamol Holdings Plc	Essential fatty acid composition
US4843095A (en)	1987-08-07	1989-06-27	Century Laboratories, Inc.	Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en)	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
IE63225B1 (en)	1988-09-13	1995-04-05	Efamol Holdings	Use of fatty acids in the treatment of myalgic encephalomyelitis
GB2223943A (en)	1988-10-21	1990-04-25	Tillotts Pharma Ag	Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en)	1988-12-19	1990-06-19	Pharmacaps, Inc.	Chewable, edible soft gelatin capsule
JP2839276B2 (ja)	1989-01-23	1998-12-16	日本分光工業株式会社	超臨界流体抽出・分離方法及び装置
US5457130A (en)	1989-03-20	1995-10-10	Cancer Research Campaign Technology Limited	Eicosapentaenoic acid used to treat cachexia
GB8906369D0 (en)	1989-03-20	1989-05-04	Tisdale Michael J	Eicosapentaenoic acid
CA2043615C (en)	1990-06-04	2001-08-14	Kazuhiko Hata	Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en)	1990-06-06	1990-07-25	Efamol Holdings	Essential fatty acid treatment
JP3103588B2 (ja)	1990-11-16	2000-10-30	持田製薬株式会社	リポプロテイン（ａ）低下剤
SE9101642D0 (sv)	1991-05-30	1991-05-30	Kabi Pharmacia Ab	Phospholipids
US5215630A (en)	1991-06-04	1993-06-01	Nippon Suisan Kaisha, Ltd.	Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
WO1993003450A1 (en) *	1991-07-30	1993-02-18	North Carolina State University	Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (de)	1991-10-11	1993-10-07	Fresenius Ag	Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja)	1991-10-28	2003-04-28	日本水産株式会社	高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja)	1992-07-28	1994-02-22	Maruha Corp	ω−３不飽和脂肪酸系化合物の安定化法
US5888541A (en)	1992-08-21	1999-03-30	Scotia Holdings Plc	Fatty acid treatment
GB9217780D0 (en)	1992-08-21	1992-10-07	Efamol Holdings	Fatty acid treatment
GB9300125D0 (en)	1993-01-06	1993-03-03	Scotia Holdings Plc	Compositions containing esters of unsaturated fatty acids
WO1994028891A1 (en)	1993-06-04	1994-12-22	Martek Biosciences Corporation	Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en)	1994-03-01	1994-04-20	Scotia Holdings Plc	Fatty acid derivatives
US5760081A (en)	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en)	1994-06-28	1999-10-14	Scotia Holdings Plc	Compositions for treatment of diabetic complications
IT1274734B (it)	1994-08-25	1997-07-24	Prospa Bv	Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en)	1995-05-01	2004-10-30	Scarista Ltd	1,3-propane diol derivatives as bioactive compounds
GB9519661D0 (en)	1995-09-27	1995-11-29	Scotia Holdings Plc	Fatty acid treatment
WO1997039759A2 (en)	1996-04-24	1997-10-30	Brigham And Women's Hospital	Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
TW425285B (en)	1996-06-10	2001-03-11	Viva America Marketing Inc	Fish oil and garlic nutritive supplement
US5861399A (en)	1996-07-17	1999-01-19	Heart Care Partners	Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en)	1996-10-02	2002-05-09	Bockow Barry I.	Compositions and methods for treating cardiovascular conditions
JP4151853B2 (ja)	1996-10-11	2008-09-17	スカリスタリミテッド	エイコサペンタエン酸および／またはステアリドン酸を含む治療用薬剤
US20010006644A1 (en)	1997-07-31	2001-07-05	David J. Bova	Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
WO1999022719A1 (fr)	1997-10-30	1999-05-14	Morishita Jintan Co., Ltd.	Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
KR100587551B1 (ko)	1997-12-10	2006-06-08	싸이클로스포린 테라퓨틱스 리미티드	오메가-3 지방산 오일을 함유하는 약학 조성물
US20020055529A1 (en)	1998-12-02	2002-05-09	Bisgaier Charles Larry	Method for treating alzheimer's disease
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en)	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en)	1999-03-01	2001-02-27	Banner Pharmacaps, Inc.	Gum acacia substituted soft gelatin capsules
DK1072198T3 (da)	1999-07-28	2008-09-22	Swiss Caps Rechte & Lizenzen	Præparat til anvendelse som medikament og/eller ernæringstilskud
WO2001015552A1 (en)	1999-08-30	2001-03-08	Ocean Nutrition Canada Ltd.	A nutritional supplement for lowering serum triglyceride and cholesterol levels
ES2246769T3 (es)	2000-05-22	2006-03-01	Pro Aparts - Investimentos E Consultoria Lda	Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
GB0016045D0 (en)	2000-06-29	2000-08-23	Laxdale Limited	Therapeutic combinations of fatty acids
CN1735416A (zh)	2000-08-15	2006-02-15	辉瑞产品公司	治疗剂组合
ITMI20010129A1 (it)	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en)	2001-05-09	2001-06-27	Laxdale Ltd	Potentiation of therapeutic effects of fatty acids
NZ529339A (en)	2001-05-30	2004-08-27	Laxdale Ltd	Coenzyme Q and eicosapentaenoic acid (EPA)
ITMI20012384A1 (it)	2001-11-12	2003-05-12	Quatex Nv	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it)	2002-02-12	2003-08-12	Victorix Assets Ltd	Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
HUP0200686A2 (hu)	2002-02-22	2003-09-29	EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft.	Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
US20030166614A1 (en)	2002-03-01	2003-09-04	Harrison Stanley F.	Method for reducing cholesterol and triglycerides
CA2390820A1 (en) *	2002-06-17	2003-12-17	St. Vincent's Hospital Sydney Limited	Methods of diagnosis, prognosis and treatment of cardiovascular disease
WO2004017958A1 (ja)	2002-08-20	2004-03-04	Nikken Chemicals Co., Ltd.	軟カプセル剤
CA2506611A1 (en)	2002-11-22	2004-06-10	Nippon Suisan Kaisha Ltd.	External composition containing polyunsaturated fatty acid or its salt or ester
GB0228079D0 (en)	2002-12-02	2003-01-08	Laxdale Ltd	Huntington's Disease
WO2004078166A2 (en)	2003-03-05	2004-09-16	Solvay Pharmaceuticals Gmbh	Use of omega-3-fatty acids in the treatment of diabetic patients
MXPA05009933A (es)	2003-03-18	2005-11-04	Novartis Ag	Composiciones que comprenden acidos grasos y aminoacidos.
ITMI20032247A1 (it)	2003-11-19	2005-05-20	Tiberio Bruzzese	Interazione di derivati polari di composti insaturi con substrati inorganici
EP1711173A2 (en)	2003-12-31	2006-10-18	Igennus Limited	Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
US7022713B2 (en)	2004-02-19	2006-04-04	Kowa Co., Ltd.	Hyperlipemia therapeutic agent
US20050272095A1 (en) *	2004-05-19	2005-12-08	Ppd Biomarker Discovery Sciences, Llc	Methods of identifying biomarkers
JP2007284350A (ja)	2004-07-27	2007-11-01	Takeda Chem Ind Ltd	糖尿病治療剤
ITRM20040395A1 (it)	2004-08-03	2004-11-03	Sigma Tau Ind Farmaceuti	Composizione comprendente statine e acidi grassi omega 3.
EP1786414A4 (en)	2004-08-06	2008-04-09	Transform Pharmaceuticals Inc	NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
CN101014332A (zh)	2004-09-13	2007-08-08	参天制药株式会社	角膜结膜病变治疗剂
CN1759834B (zh) *	2004-09-17	2010-06-23	中国医学科学院医药生物技术研究所	黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
CA2581816A1 (en)	2004-09-27	2006-04-06	Sigmoid Biotechnologies Limited	Microcapsules comprising a methylxanthine and a corticosteroid
EP1833313A2 (en)	2004-10-15	2007-09-19	Corporation Limited Photonz	Compositions containing high omega-3 and low saturated fatty acid levels
FR2878747B1 (fr)	2004-12-03	2007-03-30	Pierre Fabre Medicament Sa	Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
US20070191467A1 (en)	2004-12-06	2007-08-16	Reliant Pharmaceutical, Inc.	Statin and omega-3 fatty acids for lipid therapy
BRPI0518398A2 (pt)	2004-12-06	2008-11-18	Reliant Pharmaceuticals Inc	Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
US20060135610A1 (en)	2004-12-22	2006-06-22	Bortz Jonathan D	Cardiovascular compositions
GB2421909A (en)	2004-12-23	2006-07-12	Laxdale Ltd	Pharmaceutical compositions comprising EPA and methods of use
US20060189682A1 (en) *	2005-02-02	2006-08-24	Payne Joseph E	Water soluble prodrugs of COX-2 inhibitors
WO2006096806A2 (en)	2005-03-08	2006-09-14	Reliant Pharmaceutiacals, Inc.	Treatment with statin and omega-3 fatty acids and a combination product thereof
KR101465715B1 (ko)	2005-07-08	2014-11-27	모치다 세이야쿠 가부시키가이샤	심혈관 이벤트 발병 예방용 조성물
RU2290185C1 (ru) *	2005-07-26	2006-12-27	Дмитрий Николаевич Мясников	Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
EP1919285A2 (en)	2005-07-28	2008-05-14	Reliant Pharmaceuticals, Inc.	Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (it)	2005-08-10	2007-02-11	Tiberio Bruzzese	Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
EP1948168A4 (en)	2005-10-28	2010-10-06	Numerate Inc	COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND / OR HMG-COA REDUCTASE
US20070104779A1 (en)	2005-11-07	2007-05-10	Rongen Roelof M	Treatment with omega-3 fatty acids and products thereof
US8962682B2 (en)	2005-11-11	2015-02-24	Mochida Pharmaceutical Co., Ltd.	Jelly composition
EP2364701A1 (en)	2005-12-20	2011-09-14	Cenestra, Llc	Omega-3 fatty acid formulations
PL1800675T4 (pl)	2005-12-23	2012-02-29	Nutricia Nv	Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
EP2526937A1 (en) *	2006-02-07	2012-11-28	Mochida Pharmaceutical Co., Ltd.	Composition for prevention of recurrence of stroke
WO2007128801A1 (en)	2006-05-08	2007-11-15	Novartis Ag	Combination of organic compounds
EP2777701A1 (en)	2006-05-31	2014-09-17	Mochida Pharmaceutical Co., Ltd.	Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid
NZ573719A (en)	2006-07-05	2011-08-26	Photonz Corp Ltd	Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis
WO2008012329A2 (en)	2006-07-28	2008-01-31	V. Mane Fils	Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
CN101553221A (zh)	2006-10-10	2009-10-07	瑞莱恩特医药品有限公司	用于降低APO-B水平的抑制素和ω-3脂肪酸
US20080306154A1 (en)	2006-11-03	2008-12-11	My Svensson	Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US20080125490A1 (en)	2006-11-03	2008-05-29	My Svensson	Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
ES2524320T3 (es)	2007-01-17	2014-12-05	Mochida Pharmaceutical Co., Ltd.	Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
US20100055175A1 (en)	2007-03-06	2010-03-04	James Nugent	Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
CN102552213A (zh)	2007-06-29	2012-07-11	武田药品工业株式会社	无缝胶囊
US20090182049A1 (en)	2008-01-16	2009-07-16	Joar Arild Opheim	Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
JPWO2009142242A1 (ja)	2008-05-20	2011-09-29	持田製薬株式会社	ハイリスク患者の心血管イベント予防用組成物
EP4137128A1 (en)	2008-09-02	2023-02-22	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
ES2768091T3 (es)	2009-02-10	2020-06-19	Amarin Pharmaceuticals Ie Ltd	Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
MX350088B (es)	2009-04-29	2017-08-25	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
CN108096209A (zh)	2009-06-15	2018-06-01	阿马里纳制药公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
JP5676005B2 (ja)	2010-11-04	2015-02-25	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオアート及びクロスカルメロースナトリウムを含む組成物
US20140004183A1 (en) *	2012-06-29	2014-01-02	Amarin Pharmaceuticals Ireland Limited	Methods for treating cardiovascular disease in statin-tolerant subjects

2010
- 2010-02-09 ES ES13156122T patent/ES2768091T3/es active Active
- 2010-02-09 PT PT131561227T patent/PT2596786T/pt unknown
- 2010-02-09 PL PL10704464T patent/PL2395991T3/pl unknown
- 2010-02-09 NZ NZ594395A patent/NZ594395A/en unknown
- 2010-02-09 SI SI201031979T patent/SI2596786T1/sl unknown
- 2010-02-09 CA CA3089847A patent/CA3089847C/en active Active
- 2010-02-09 HU HUE16152447A patent/HUE048299T2/hu unknown
- 2010-02-09 DK DK13156122.7T patent/DK2596786T3/da active
- 2010-02-09 ES ES16152447T patent/ES2769926T3/es active Active
- 2010-02-09 SI SI201030313T patent/SI2395991T1/sl unknown
- 2010-02-09 PT PT161524475T patent/PT3037089T/pt unknown
- 2010-02-09 MX MX2011008448A patent/MX2011008448A/es active IP Right Grant
- 2010-02-09 PL PL13156122T patent/PL2596786T3/pl unknown
- 2010-02-09 EP EP16152447.5A patent/EP3037089B1/en not_active Revoked
- 2010-02-09 LT LTEP13156122.7T patent/LT2596786T/lt unknown
- 2010-02-09 BR BRPI1007518-6A patent/BRPI1007518A2/pt not_active IP Right Cessation
- 2010-02-09 KR KR1020117019164A patent/KR101383006B1/ko active Active
- 2010-02-09 SG SG2011057353A patent/SG173612A1/en unknown
- 2010-02-09 DK DK10704464.6T patent/DK2395991T3/da active
- 2010-02-09 EP EP19193487.6A patent/EP3616694A1/en not_active Withdrawn
- 2010-02-09 WO PCT/US2010/023638 patent/WO2010093634A1/en not_active Ceased
- 2010-02-09 EP EP13156122.7A patent/EP2596786B1/en not_active Revoked
- 2010-02-09 SI SI201031980T patent/SI3037089T1/sl unknown
- 2010-02-09 EP EP10704464.6A patent/EP2395991B1/en not_active Revoked
- 2010-02-09 KR KR1020137034936A patent/KR20140007973A/ko not_active Withdrawn
- 2010-02-09 US US12/702,889 patent/US8293727B2/en not_active Expired - Fee Related
- 2010-02-09 PT PT107044646T patent/PT2395991E/pt unknown
- 2010-02-09 EP EP21152120.8A patent/EP3865128B1/en active Active
- 2010-02-09 RU RU2011137415/15A patent/RU2505292C2/ru active
- 2010-02-09 HR HRP20130811AT patent/HRP20130811T1/hr unknown
- 2010-02-09 LT LTEP16152447.5T patent/LT3037089T/lt unknown
- 2010-02-09 SM SM20200078T patent/SMT202000078T1/it unknown
- 2010-02-09 AU AU2010213899A patent/AU2010213899B2/en active Active
- 2010-02-09 CA CA2751576A patent/CA2751576C/en active Active
- 2010-02-09 PL PL16152447T patent/PL3037089T3/pl unknown
- 2010-02-09 CA CA3008079A patent/CA3008079C/en active Active
- 2010-02-09 SM SM20200079T patent/SMT202000079T1/it unknown
- 2010-02-09 SG SG10201610916SA patent/SG10201610916SA/en unknown
- 2010-02-09 ES ES10704464T patent/ES2426132T3/es active Active
- 2010-02-09 SG SG10201400685SA patent/SG10201400685SA/en unknown
- 2010-02-09 DK DK16152447.5T patent/DK3037089T3/da active
2011
- 2011-07-29 ZA ZA2011/05612A patent/ZA201105612B/en unknown
- 2011-08-04 US US13/198,221 patent/US20110288171A1/en not_active Abandoned
- 2011-10-26 US US13/282,145 patent/US8318715B2/en not_active Expired - Fee Related
- 2011-10-28 US US13/284,408 patent/US8314086B2/en not_active Expired - Fee Related
2012
- 2012-01-12 US US13/349,153 patent/US8293728B2/en not_active Expired - Fee Related
- 2012-01-12 US US13/349,150 patent/US8324195B2/en not_active Expired - Fee Related
- 2012-01-12 US US13/349,157 patent/US8415335B2/en not_active Expired - Fee Related
- 2012-02-23 US US13/403,694 patent/US20120156285A1/en not_active Abandoned
- 2012-02-24 US US13/404,666 patent/US20120157530A1/en not_active Abandoned
- 2012-05-29 US US13/482,720 patent/US20120237594A1/en not_active Abandoned
- 2012-09-10 US US13/608,744 patent/US8426399B2/en not_active Expired - Fee Related
- 2012-09-10 US US13/608,775 patent/US8357677B1/en not_active Expired - Fee Related
- 2012-09-11 US US13/610,217 patent/US8399446B2/en not_active Expired - Fee Related
- 2012-09-11 US US13/610,247 patent/US8367652B2/en not_active Expired - Fee Related
- 2012-09-20 US US13/623,450 patent/US8377920B2/en not_active Expired - Fee Related
- 2012-12-11 US US13/711,329 patent/US8431560B1/en not_active Expired - Fee Related
- 2012-12-11 US US13/711,324 patent/US8440650B1/en not_active Expired - Fee Related
2013
- 2013-02-25 US US13/776,261 patent/US8546372B2/en active Active
- 2013-02-25 US US13/776,249 patent/US8524698B2/en active Active
- 2013-02-25 US US13/776,242 patent/US8518929B2/en active Active
- 2013-05-28 US US13/903,742 patent/US20130331447A1/en not_active Abandoned
- 2013-09-05 SM SM201300095T patent/SMT201300095B/xx unknown
- 2013-12-10 RU RU2013154780A patent/RU2686315C2/ru active
2015
- 2015-02-25 PH PH12015500407A patent/PH12015500407B1/en unknown
2017
- 2017-01-17 US US15/408,077 patent/US20170119722A1/en not_active Abandoned
2018
- 2018-02-28 US US15/907,707 patent/US20180185320A1/en not_active Abandoned
- 2018-07-06 US US16/029,198 patent/US20190038590A1/en not_active Abandoned
2020
- 2020-01-16 HR HRP20200068TT patent/HRP20200068T1/hr unknown
- 2020-01-16 HR HRP20200065TT patent/HRP20200065T1/hr unknown
- 2020-02-04 CY CY20201100099T patent/CY1122628T1/el unknown
- 2020-02-04 CY CY20201100100T patent/CY1122629T1/el unknown
- 2020-04-21 US US16/854,757 patent/US20200246300A1/en not_active Abandoned
- 2020-09-01 US US17/009,597 patent/US20210046036A1/en not_active Abandoned
- 2020-11-23 US US17/101,700 patent/US20210069142A1/en not_active Abandoned
2021
- 2021-01-20 US US17/153,494 patent/US20210251941A1/en not_active Abandoned
2023
- 2023-02-24 US US18/174,091 patent/US20240024277A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20130096197A1 (en)	2013-04-18
PT2395991E (pt)	2013-09-03
PL2395991T3 (pl)	2013-11-29
AU2010213899B2 (en)	2014-02-06
CA3089847C (en)	2024-04-09
CA3008079C (en)	2020-09-22
US8431560B1 (en)	2013-04-30
CY1122629T1 (el)	2021-03-12
US8293727B2 (en)	2012-10-23
SI3037089T1 (sl)	2020-03-31
DK2596786T3 (da)	2020-02-24
RU2505292C2 (ru)	2014-01-27
US20170119722A1 (en)	2017-05-04
US8399446B2 (en)	2013-03-19
US20120237594A1 (en)	2012-09-20
US20130171250A1 (en)	2013-07-04
US20120156285A1 (en)	2012-06-21
US20130102674A1 (en)	2013-04-25
EP3865128A1 (en)	2021-08-18
RU2686315C2 (ru)	2019-04-25
HRP20130811T1 (en)	2013-09-30
DK2395991T3 (da)	2013-09-02
EP3037089A1 (en)	2016-06-29
HUE048299T2 (hu)	2020-07-28
US20210251941A1 (en)	2021-08-19
CY1122628T1 (el)	2021-03-12
ES2769926T3 (es)	2020-06-29
EP3865128B1 (en)	2026-05-13
HK1165698A1 (en)	2012-10-12
PL2596786T3 (pl)	2020-06-01
CA2751576C (en)	2018-07-03
PT3037089T (pt)	2020-03-04
US20180185320A1 (en)	2018-07-05
US8426399B2 (en)	2013-04-23
ZA201105612B (en)	2012-10-31
SMT201300095B (it)	2013-11-08
US8293728B2 (en)	2012-10-23
KR101383006B1 (ko)	2014-04-08
US20120039997A1 (en)	2012-02-16
CA3008079A1 (en)	2010-08-19
EP2395991A1 (en)	2011-12-21
PT2596786T (pt)	2020-03-04
US20200246300A1 (en)	2020-08-06
US20190038590A1 (en)	2019-02-07
US8524698B2 (en)	2013-09-03
US8440650B1 (en)	2013-05-14
US20120108659A1 (en)	2012-05-03
SMT202000078T1 (it)	2020-03-13
US20130004568A1 (en)	2013-01-03
SG10201400685SA (en)	2015-01-29
US20120108660A1 (en)	2012-05-03
US20120108663A1 (en)	2012-05-03
EP3616694A1 (en)	2020-03-04
CA3089847A1 (en)	2010-08-19
MX2011008448A (es)	2012-02-28
US20210069142A1 (en)	2021-03-11
US8377920B2 (en)	2013-02-19
SG10201610916SA (en)	2017-02-27
HRP20200065T1 (hr)	2020-04-03
SI2596786T1 (sl)	2020-03-31
EP2596786B1 (en)	2019-11-27
US20130164375A1 (en)	2013-06-27
HRP20200068T1 (hr)	2020-04-03
US8415335B2 (en)	2013-04-09
ES2768091T3 (es)	2020-06-19
US20130331447A1 (en)	2013-12-12
RU2013154780A (ru)	2015-06-20
US8367652B2 (en)	2013-02-05
US8518929B2 (en)	2013-08-27
US20110288171A1 (en)	2011-11-24
HK1226307A1 (en)	2017-09-29
US20210046036A1 (en)	2021-02-18
EP2395991B1 (en)	2013-05-29
SMT202000079T1 (it)	2020-03-13
US20130017256A1 (en)	2013-01-17
US20130004567A1 (en)	2013-01-03
PH12015500407A1 (en)	2015-09-21
PL3037089T3 (pl)	2020-06-01
US8357677B1 (en)	2013-01-22
CA2751576A1 (en)	2010-08-19
WO2010093634A1 (en)	2010-08-19
SG173612A1 (en)	2011-09-29
US8324195B2 (en)	2012-12-04
US20120157530A1 (en)	2012-06-21
US8546372B2 (en)	2013-10-01
EP3037089B1 (en)	2019-11-27
US20120093924A1 (en)	2012-04-19
BRPI1007518A2 (pt)	2018-02-20
RU2011137415A (ru)	2013-03-20
US8318715B2 (en)	2012-11-27
KR20110110321A (ko)	2011-10-06
ES2426132T3 (es)	2013-10-21
KR20140007973A (ko)	2014-01-20
LT2596786T (lt)	2020-01-10
PH12015500407B1 (en)	2015-09-21
US20130171249A1 (en)	2013-07-04
RU2019111131A (ru)	2020-10-15
EP2596786A1 (en)	2013-05-29
US8314086B2 (en)	2012-11-20
US20240024277A1 (en)	2024-01-25
AU2010213899A1 (en)	2011-08-25
DK3037089T3 (da)	2020-01-20
US20130005809A1 (en)	2013-01-03
NZ594395A (en)	2014-01-31
US20130004566A1 (en)	2013-01-03
SI2395991T1 (sl)	2013-12-31
US20100311834A1 (en)	2010-12-09

Publication	Publication Date	Title
DK2623507T3 (da)	2017-01-02	Morpholinonukleinsyrederivat
LT2596786T (lt)	2020-01-10	Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti
BRPI1013937A2 (pt)	2016-08-09	compostos de ácido carboxílico
BRPI1009197A2 (pt)	2015-09-15	preparação de ácido alfa-cetopimélico
EP2442645A4 (en)	2013-03-06	choline
DK2421808T3 (da)	2013-11-04	4-Hydroxysmørsyreanaloger
DK2562155T3 (da)	2019-06-24	Hydroxaminsyrederivat
DK2361256T3 (da)	2013-07-01	Cyclohexenyl-nukleinsyreanaloger
DOP2011000086A (es)	2011-04-15	Derivados de acido 1-amino-2-ciclobutiletilboronico
BRPI0913368A2 (pt)	2015-11-24	compostos de ácido carboxílico
IL214446A0 (en)	2011-09-27	Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
IL219314A0 (en)	2012-06-28	Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
EP2281080A4 (en)	2012-10-10	POLYLACTIC ACID FIBERS
HRP20190509T1 (hr)	2019-05-03	Spoj piridilaminooctene kiseline
EP2475761A4 (en)	2015-04-22	PHOTO BIOREACTOR
DK2234994T3 (da)	2017-11-13	Fedtsyre-butylester-blandinger
BRPI1011650A2 (pt)	2016-03-22	composições sólidas compreendendo ácido 5-aminolevulínico
EP2408299A4 (en)	2012-08-15	FATTY ACID MONOGLYCERIDE COMPOSITIONS
BRPI1009018A2 (pt)	2015-12-01	fotobiorreator
FR2952847B3 (fr)	2011-12-09	>
DOP2011000242A (es)	2011-09-15	Macrolido anti-inflamatorio
EP2542232A4 (en)	2013-08-28	FATTY ACID INHIBITORS
ITPD20090053U1 (it)	2011-04-10	Paradordi per banchine
BRPI1015272A2 (pt)	2015-08-25	Fermentação
GB0904300D0 (en)	2009-04-22	Essential fatty acid compounds